PeproStat Haemostat Study in Subjects Undergoing Liver Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-07-31

Study Completion Date

2015-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this First in Man study is to evaluate the safety and tolerability, as well as to explore efficacy of PeproStat, a new peptide based coagulant (haemostat), when used in patients undergoing open liver resection surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

WEUSKOP5410: Observational Study in ENABLE Clinical Trials

NCT01458080

Hepatitis C

COMPLETED

Clinical Study of Lyophilized Plasma in Patients With Liver Disease

NCT01547078

Liver Disease

WITHDRAWN PHASE2

Study of Mediators of Post Hepatectomy Liver Regeneration

NCT02077062

Mediators of Post Hepatectomy Liver Regeneration

TERMINATED

The Effect of GLP-1 Analogues on Liver Steatosis and Fibrosis in Diabetic and Obese Patients in a Clinical Setting

NCT07021443

Non-Alcoholic Fatty Liver Disease

COMPLETED

Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy

NCT03179995

Major Liver Resection

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemorrhage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Haemostat

PeproStat

Group Type EXPERIMENTAL

PeproStat

Intervention Type DRUG

A solution of PeproStat containing up to 9.25mg protein soaked immediately prior to use onto a Gelita-Spon® gelatin sponge.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PeproStat

A solution of PeproStat containing up to 9.25mg protein soaked immediately prior to use onto a Gelita-Spon® gelatin sponge.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Are able and willing to provide written informed consent to participate in this study, confirmed by signing the informed consent documents
* Adult males and females ≥18 years of age
* Female subjects must be post-menopausal. Post-menopausal status is defined as any of the following: natural menopause with menses \>1 year ago; radiation induced oophorectomy with last menses \>1 year ago; chemotherapy induced menopause with 1 year interval since last menses
* Willing and able to comply with all protocol requirements including follow-up
* Subject must have a haemoglobin ≥ 9.0 g/dL at screening
* Subject must have a platelet count ≥ 100,000/mm3 at screening
* Subject is undergoing a planned open liver resection
* Male subjects must be willing and able to use adequate contraception from enrollment through to the 30 day follow-up visit
* During the surgery, the subject presents an identified target bleeding site (TBS) with oozing, mild or moderate bleeding, which conventional surgical techniques are insufficient to control and would otherwise be a candidate for standard haemostats
* During the surgery, subject presents no intraoperative complications, other than bleeding, that may interfere with study assessments as judged by the investigator

Exclusion Criteria

* Subject is undergoing emergency surgical procedure
* Recipient of a liver transplant
* Females of child-bearing potential
* Active infection at the time of the liver resection
* International Normalized Ratio (INR) \> 2.0 or APTT ratio \> 2.0 at screening
* Fibrinogen level \< 1.5g/L at screening
* History of thromboembolic disease and/or thrombophilia
* Any other disease or condition that may affect normal blood clotting, for example thrombocytopenia, as judged by the investigator
* A known history of anaphylaxis or allergic reaction to human albumin, PEGylated proteins, yeast or moulds, porcine products or other components in the IMP
* Participation in another investigational drug or device research study within 30 days before and after enrolment in the current study
* Current known or suspected alcohol and/or drug abuse or dependence at the time of screening
* Any concurrent medical, surgical, or psychiatric condition that may, in the investigator's opinion, affect the subject's willingness or ability to meet all study requirements during the study duration
* During the surgery, subject presents severe bleeding where use of a topical haemostat would be inappropriate
* Subject is taking any prohibited medications
* BMI at screening of ≥35

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No